Michael Cohen-Wolkowiez

Michael Cohen-Wolkowiez

Auto-generated profile, based on publicly available information

Michael Cohen-Wolkowiez

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Clinics in Perinatology
Verified
Journal Article
Closed access
LKLawrence C. Ku
Lawrence C. Ku
KBKim A. Boggess
Kim A. Boggess
MCMichael Cohen-Wolkowiez
Michael Cohen-Wolkowiez

1 May 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
MCMichael Cohen-Wolkowiez
Michael Cohen-Wolkowiez
KWKevin M. Watt
Kevin M. Watt
CZChenguang Zhou
Chenguang Zhou
BBBarry T. Bloom
Barry T. Bloom
BPBrenda Poindexter
Brenda Poindexter
PSP. Brian Smith
P. Brian Smith
Piperacillin-tazobactam is often given to infants with severe infection in spite of limited pharmacokinetics (PK) data. We evaluated piperacillin-tazobactam PK in premature and term infants of ages <61 days with suspected systemic infection. Infants received intravenous piperacillin-tazobactam (80 to 100 mg/kg of body weight every 8 h [q 8 h]) based on gestational and postnatal age. Sparse plasma samples were obtained after first and multiple doses. Drug concentrations were measured by tandem mass spectrometry. PK data were analyzed using population nonlinear mixed-effect modeling. Target attainment rates for the time unbound piperacillin concentrations remained above the MIC for 50% and 75% of the dosing interval at steady state were evaluated. Bias in population PK parameter estimates was assessed for dried blood spot (DBS) samples, and a comparability analysis was performed for DBS and plasma drug concentrations using linear regression. We obtained 128 plasma samples from 32 infants, median gestational age of 30 weeks (range, 23 to 40 weeks) and postnatal age of 8 days (range, 1 to 60). Piperacillin and tazobactam PK models included body weight (WT) and postmenstrual age (PMA) as covariates for clearance and WT for volume of distribution and were used to optimize dosing in infants. DBS drug concentrations were 50 to 60% lower than those in plasma, but when combined with plasma concentrations and a matrix effect, the data generated PK model parameters similar to those for plasma alone. With PMA-based dosing (100 mg/kg q 8 h, 80 mg/kg q 6 h, and 80 mg/kg q 4 h for PMA of ≤30, 30 to 35, and 35 to 49 weeks, respectively), 90% of simulated infants achieved the surrogate therapeutic target of time above the MIC (≤32 mg/liter) for 75% of the dosing interval.

6 July 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
CNCody S. Nelson
Cody S. Nelson
DCDiana Vera Cruz
Diana Vera Cruz
DTDollnovan Tran
Dollnovan Tran
KBKristy M. Bialas
Kristy M. Bialas
LSLisa Stamper
Lisa Stamper
SPSallie R. Permar
Sallie R. Permar
Human cytomegalovirus (HCMV) is the most common congenital infection and a known cause of microcephaly, sensorineural hearing loss, and cognitive impairment among newborns worldwide. Natural maternal HCMV immunity reduces the incidence of congenital infection, but does not prevent the disease altogether. We employed a nonhuman primate model of congenital CMV infection to investigate the ability of preexisting antibodies to protect against placental CMV transmission in the setting of primary maternal infection and subsequent viremia, which is required for placental virus exposure. Pregnant, CD4 + T cell–depleted, rhesus CMV–seronegative (RhCMV-seronegative) rhesus monkeys were treated with either standardly produced hyperimmune globulin (HIG) from RhCMV-seropositive macaques or dose-optimized, potently RhCMV-neutralizing HIG prior to intravenous challenge with an RhCMV mixture. HIG passive infusion provided complete protection against fetal loss in both groups. The dose-optimized, RhCMV-neutralizing HIG additionally inhibited placental transmission of RhCMV and reduced viral replication and diversity. Our findings suggest that the presence of durable and potently neutralizing antibodies at the time of primary infection can prevent transmission of systemically replicating maternal RhCMV to the developing fetus, and therefore should be a primary target of vaccines to eliminate this neonatal infection.

20 June 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
DGD Gonzalez
D Gonzalez
CMC Melloni
C Melloni
RYR Yogev
R Yogev
BPB B Poindexter
B B Poindexter
SMS R Mendley
S R Mendley
MCM Cohen-Wolkowiez
M Cohen-Wolkowiez
Clindamycin is commonly prescribed to treat children with skin and skin‐structure infections (including those caused by community‐acquired methicillin‐resistant Staphylococcus aureus (CA‐MRSA)), yet ...

16 March 2011 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MCM Cohen-Wolkowiez
M Cohen-Wolkowiez
DBD K Benjamin
D K Benjamin
LPL Piper
L Piper
ICI M Cheifetz
I M Cheifetz
CMC Moran
C Moran
PSP B Smith
P B Smith

1 June 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
ATAdriana Tremoulet
Adriana Tremoulet
JLJennifer Le
Jennifer Le
BPBrenda Poindexter
Brenda Poindexter
JSJanice E. Sullivan
Janice E. Sullivan
MLMatthew Laughon
Matthew Laughon
MCMichael Cohen-Wolkowiez
Michael Cohen-Wolkowiez
Although ampicillin is the most commonly used drug in neonates, developmental pharmacokinetic (PK) data to guide dosing are lacking. Ampicillin is primarily renally eliminated, and developmental changes are expected to influence PK. We conducted an open-label, multicenter, opportunistic, prospective PK study of ampicillin in neonates stratified by gestational age (GA) (≤34 or >34 weeks) and postnatal age (PNA) (≤7 or >7 days). Drug concentrations were measured by tandem mass spectrometry. PK data were analyzed using population nonlinear mixed-effects modeling in NONMEM 7.2. Monte Carlo simulations were conducted to determine the probability of target attainment for the time in which the total steady-state ampicillin concentrations remained above the MIC ( T >MIC) for 50%, 75%, and 100% of the dosing interval. A total of 142 PK samples from 73 neonates were analyzed (median [range] GA, 36 [24 to 41] weeks; PNA, 5 [0 to 25] days). The median ampicillin dose was 200 (100 to 350) mg/kg/day. Postmenstrual age and serum creatinine were covariates for ampicillin clearance (CL). A simplified dosing regimen of 50 mg/kg every 12 h for GA of ≤34 weeks and PNA of ≤7 days, 75 mg/kg every 12 h for GA of ≤34 weeks and PNA of ≥8 and ≤28 days, and 50 mg/kg every 8 h for GA of >34 weeks and PNA of ≤28 days achieved the prespecified surrogate efficacy target in 90% of simulated subjects. Ampicillin CL was associated with neonatal development. A simplified dosing regimen stratified by GA and PNA achieves the desired surrogate therapeutic target in the vast majority of neonates.